ライフサイエンスコーパス: dolutegravir

1 ncentration of the viral integrase inhibitor dolutegravir.

2 d a phase 2 trial comparing bictegravir with dolutegravir.

3 ribed DRMs that emerge in patients receiving dolutegravir.

4 the second generation INST inhibitor (INSTI) dolutegravir.

5 se subtypes can influence resistance against dolutegravir.

6 een reported for naive patients treated with dolutegravir.

7 rted (>/=10%) adverse events were diarrhoea (dolutegravir 41 [17%] patients vs darunavir plus ritonav

8 re randomly assigned (1:1) to receive either dolutegravir 50 mg once daily or darunavir 800 mg plus r

9 Patients were randomly assigned (1:1) to dolutegravir 50 mg or darunavir 800 mg plus ritonavir 10

10 Dolutegravir 50 mg twice daily with an optimized backgro

11 e 200 mg, and tenofovir alafenamide 25 mg or dolutegravir 50 mg with coformulated emtricitabine 200 m

12 tenofovir alafenamide 25 mg or coformulated dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300

13 ety and efficacy data of regimens containing dolutegravir (50 mg twice daily) in antiretroviral-exper

14 nd tenofovir alafenamide than in those given dolutegravir, abacavir, and lamivudine (10% [n=32] vs 23

15 itabine, and tenofovir alafenamide than with dolutegravir, abacavir, and lamivudine (26% [n=82] vs 40

16 enofovir alafenamide (n=316) or coformulated dolutegravir, abacavir, and lamivudine (n=315), of whom

17 gher incidence of drug-related nausea in the dolutegravir, abacavir, and lamivudine group (5% [n=17]

18 and 93.0% of patients (n=293 of 315) in the dolutegravir, abacavir, and lamivudine group (difference

19 adults and was non-inferior to coformulated dolutegravir, abacavir, and lamivudine, with no treatmen

20 th better gastrointestinal tolerability than dolutegravir, abacavir, and lamivudine.

21 emtricitabine, and tenofovir alafenamide to dolutegravir, abacavir, and lamivudine.

22 a fixed-dose combination versus coformulated dolutegravir, abacavir, and lamivudine.

23 r alafenamide as a fixed-dose combination to dolutegravir administered with coformulated emtricitabin

24 At week 48, 217 (90%) patients receiving dolutegravir and 200 (83%) patients receiving darunavir

25 ded in the analysis (242 assigned to receive dolutegravir and 242 assigned to receive ritonavir-boost

26 Adverse events were similar between the dolutegravir and atazanavir groups; the most common were

27 some non-B HIV subtype viruses treated with dolutegravir and will aid in the inhibition of such a vi

28 A transition to use of a dolutegravir as a first-line regimen in all new ART init

29 Participants were randomly assigned to dolutegravir at a dose of 50 mg plus abacavir-lamivudine

30 reduced risk of resistance acquisition with dolutegravir-based regimens and reduced use of expensive

31 The transition to dolutegravir-based regimens in PEPFAR-supported countrie

32 Median dolutegravir C12h was 4086 (1756-5717 ng/mL) ng/mL in 9

33 r efficacy and similar safety profile of the dolutegravir combined regimen compared with the atazanav

34 Dolutegravir compares favourably in efficacy and safety

35 Optimized dolutegravir-containing antiretroviral regimens supporte

36 ved the first second generation INSTI, GSK's Dolutegravir (DTG) (August 2013).

37 evaluating the efficacy of dual therapy with dolutegravir (DTG) and lamivudine (3TC).

38 odeficiency virus (HIV) type 1 RNA decay and dolutegravir (DTG) concentrations in the semen of HIV-in

39 Dolutegravir (DTG) is the latest antiretroviral (ARV) ap

40 pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV)

41 Dolutegravir (DTG), a next-generation integrase strand t

42 Dolutegravir (DTG), a once-daily, human immunodeficiency

43 d drugs, raltegravir (RAL), elvitegravir and dolutegravir (DTG), act as interfacial inhibitors during

44 The second-generation agent, dolutegravir (DTG), has enjoyed considerable clinical su

45 With no IR testing, all patients start dolutegravir (DTG)-based ART after genotype; 12-week sup

46 Dolutegravir (DTG; S/GSK1349572), a human immunodeficien

47 d be an integrase strand transfer inhibitor (dolutegravir, elvitegravir, or raltegravir), a nonnucleo

48 th the atazanavir regimen support the use of dolutegravir for HIV-1 infection in treatment-naive wome

49 containing efavirenz to regimens containing dolutegravir formulations in adult ART initiators is pre

50 s or stopping criteria was less frequent for dolutegravir (four [2%] patients) than for darunavir plu

51 common in the bictegravir group than in the dolutegravir group (57 [18%] of 320 vs 83 [26%] of 325,

52 ictegravir group and 302 (93%) of 325 in the dolutegravir group (difference -3.5%, 95.002% CI -7.9 to

53 ed, 499 were randomly assigned to either the dolutegravir group (n=250) or the atazanavir group (n=24

54 per mL compared with 31 (93.9%) of 33 in the dolutegravir group (weighted difference 2.9%, 95% CI -8.

55 x participants (three since 48 weeks) in the dolutegravir group and 13 (four) in the darunavir plus r

56 t 96 weeks, 194 (80%) of 242 patients in the dolutegravir group and 164 (68%) of 242 in the ritonavir

57 eek 48, 203 (82%) of 248 participants in the dolutegravir group compared with 176 (71%) of 247 in the

58 Fewer participants in the dolutegravir group than the atazanavir group reported dr

59 t common were nausea (46 [19%] of 248 in the dolutegravir group vs 49 [20%] of 247 in the atazanavir

60 e events were diarrhoea (23/242 [10%] in the dolutegravir group vs 57/242 [24%] in the darunavir plus

61 vir plus abacavir and lamivudine once a day (dolutegravir group) or a three-tablet combination of rit

62 the bictegravir group and 1 [<1%] 325 in the dolutegravir group).

63 lus emtricitabine and tenofovir alafenamide [dolutegravir group]).

64 Dolutegravir had a good, similar safety profile with eac

65 Patients receiving dolutegravir had significantly fewer low-density lipopro

66 Dolutegravir has been shown to be non-inferior to an int

67 Dolutegravir has shown in vitro activity against human i

68 Once-daily dolutegravir in combination with fixed-dose NRTIs repres

69 als, we addressed the safety and efficacy of dolutegravir in women with HIV-1.

70 Dolutegravir, in combination with abacavir-lamivudine, m

71 ation health of postponing the transition to dolutegravir increases substantially with higher prevale

72 asma HIV-2 RNA (pVL) was assessed at time of dolutegravir initiation (baseline), month 3, and month 6

73 Dolutegravir is a once-daily integrase strand transfer i

74 Once-daily dolutegravir is associated with a higher virological res

75 s genotyping when a strong inhibitor such as dolutegravir is being used.

76 Dolutegravir is likely to have full or partial activity

77 Dolutegravir, MK-2048, and MK-0536 are equally effective

78 tudy at 48 weeks showed that patients taking dolutegravir once daily had a significantly higher virol

79 to receive either a single-tablet regimen of dolutegravir plus abacavir and lamivudine once a day (do

80 Dolutegravir plus abacavir-lamivudine had a better safet

81 combination [bictegravir group] and 330 with dolutegravir plus emtricitabine and tenofovir alafenamid

82 afenamide group versus 22 (67%) of 33 in the dolutegravir plus emtricitabine and tenofovir alafenamid

83 emtricitabine and tenofovir alafenamide and dolutegravir plus emtricitabine and tenofovir alafenamid

84 ne and tenofovir alafenamide and 33 received dolutegravir plus emtricitabine and tenofovir alafenamid

85 viruses had various levels of resistance to dolutegravir, raltegravir, and elvitegravir.

86 men was achieved and was non-inferior to the dolutegravir regimen in previously untreated adults.

87 egimen and 325 participants who received the dolutegravir regimen were included in the primary effica

88 nferiority of the bictegravir regimen to the dolutegravir regimen.

89 as safe and well tolerated compared with the dolutegravir regimen.

90 may represent the initial substitution in a dolutegravir resistance pathway.

91 High-level dolutegravir resistance was predicted in 12% of patients

92 cy virus type-1 (HIV-1) integrase inhibitors dolutegravir (S/GSK1349572) (3) and S/GSK1265744 (4).

93 Dolutegravir (S/GSK1349572), a once-daily, unboosted int

94 the interpretation of resistance patterns in dolutegravir-treated patients.

95 rity and on pre-specified secondary analysis dolutegravir was superior (p=0.025).

96 Once-daily dolutegravir was superior to once-daily darunavir plus r

97 was greater than 0%, then we concluded that dolutegravir was superior to ritonavir-boosted darunavir

98 In FLAMINGO, we compared dolutegravir with darunavir plus ritonavir in individual

99 e oral once-daily 75 mg bictegravir or 50 mg dolutegravir with matching placebo plus the fixed-dose c

100 virological failure to raltegravir received dolutegravir with optimized background antiretroviral co